GlassScriptPhysician profile
Michael J Rosen
NPI 1336285261
$140,552.85
in general payments reported to CMS, 2019-2025
24 companies · $12K in 2025
The $12K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $120 · 2021: $548 · 2022: $14K · 2023: $54K · 2024: $60K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $60K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Honoraria: $20K · Food and Beverage: $6,901 · Travel and Lodging: $6,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $59,932.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,850.00 |
| Honoraria | $19,550.00 |
| Food and Beverage | $6,901.46 |
| Travel and Lodging | $6,682.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $62,627.52 | 2022-2025 | Auvelity |
| Abbvie INC. | $48,718.21 | 2021-2025 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $14,953.11 | 2024-2025 | Cobenfy |
| Tris Pharma INC | $10,907.83 | 2022-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Supernus Pharmaceuticals, INC. | $739.54 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $339.68 | 2023-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $330.23 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $250.47 | 2022-2025 | Rexulti, Brintellix |
| Almatica Pharma LLC | $222.01 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Takeda Pharmaceuticals U.S.A., INC. | $214.30 | 2022-2024 | Trintellix |
| Alkermes, INC. | $200.38 | 2022-2025 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $152.76 | 2019-2024 | Jornay Pm |
| Eisai INC. | $141.52 | 2021 | |
| Allergan, INC. | $140.69 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $133.53 | 2022-2024 | Quviviq |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $107.88 | 2019-2024 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $95.96 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Corium, LLC | $90.78 | 2022-2024 | Azstarys |
| Neos Therapeutics, LP | $90.62 | 2021-2024 | Adzenys Xr-Odt |
| Fidia Pharma USA INC. | $23.27 | 2024 | Hymovis |
| Aytu Biopharma, INC. | $22.30 | 2022 | |
| Bausch Health US, LLC | $17.38 | 2022 | |
| Almirall LLC | $16.67 | 2019 | |
| Sandoz INC. | $16.21 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.